| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities: | |||||||||
Net loss | |||||||||
-715,075 | -361,918 | -50,688 | -267,265 | -220,030 | -135,789 | -111,985 | -121,287 | -2,318 | -32,177 |
Adjustments to reconcile net loss to cash flows from operating activities: | |||||||||
Non-cash restructuring expense | |||||||||
- | - | - | 911 | - | - | - | - | - | - |
Acquired in-process research and development | |||||||||
173,240 | - | - | - | - | - | - | 0 | - | 0 |
Non-cash up-front payment to StrideBio | |||||||||
29,415 | - | - | - | - | - | - | - | - | - |
Gain from sale of Priority Review Voucher | |||||||||
- | - | 125,000 | - | - | - | - | - | - | - |
Depreciation and amortization | |||||||||
30,547 | 12,245 | 8,092 | 5,611 | 5,247 | 3,690 | 1,277 | 1,525 | 1,300 | 1,463 |
Amortization of investment discount | |||||||||
8,445 | 7,672 | 888 | -80 | -652 | 2,432 | - | - | - | - |
Loss from debt extinguishment | |||||||||
- | -2,322 | - | - | - | - | - | - | - | - |
Non-cash interest expense | |||||||||
21,444 | 20,190 | 2,679 | 355 | 367 | 12 | - | - | - | - |
Loss on disposal of assets | |||||||||
- | - | - | -293 | -197 | -128 | -590 | -357 | -190 | -776 |
Realized gain on sale of available-for-sale securities | |||||||||
- | - | - | - | - | - | - | 0 | - | 0 |
Write-down of available-for-sale securities | |||||||||
- | - | - | - | - | - | - | 0 | - | 0 |
Impairment charge on real estate owned | |||||||||
- | - | - | - | - | - | - | 0 | 109 | 408 |
Stock-based compensation | |||||||||
78,602 | 50,127 | 30,465 | 29,962 | 32,117 | 20,345 | 11,127 | 3,078 | 3,129 | 3,169 |
Increase in warrant valuation | |||||||||
- | - | - | - | - | 2,779 | 22,027 | -91,938 | -33,022 | -11,502 |
Other | |||||||||
690 | 3,938 | 805 | - | - | - | - | - | - | - |
Changes in operating assets and liabilities, net: | |||||||||
Net increase in accounts receivable | |||||||||
41,835 | 19,576 | 24,240 | 1,251 | 1,561 | -1,114 | -1,183 | - | - | - |
Net increase in inventory | |||||||||
45,934 | 41,840 | 70,792 | 12,813 | - | - | - | - | - | - |
Net increase in other assets | |||||||||
102,091 | 136,638 | 15,354 | 9,012 | -15,249 | 34,013 | -1,618 | - | - | - |
Net increase in accounts payable, accrued expenses, lease liabilities and other liabilities | |||||||||
122,979 | 90,162 | 12,925 | 7,309 | 18,297 | 10,763 | 9,468 | -1,718 | 7,996 | 861 |
Net (increase) decrease in accounts receivable and other assets | |||||||||
- | - | - | - | - | - | - | 3,587 | 1,063 | 1,211 |
Net cash provided by (used in) operating activities | |||||||||
-456,463 | -388,660 | -231,996 | -245,820 | -149,465 | -128,539 | -64,695 | -29,694 | -23,679 | -15,209 |
Purchase of property and equipment | |||||||||
59,631 | 61,157 | 12,000 | 5,341 | 3,401 | 25,444 | 2,370 | 108 | 1,178 | 832 |
Proceeds from sale of Priority Review Voucher, net of commission | |||||||||
- | - | 125,000 | - | - | - | - | - | - | - |
Purchase of intangible assets | |||||||||
3,082 | 3,188 | 9,215 | 1,525 | 1,432 | 1,381 | 1,405 | 1,037 | 1,127 | 1,122 |
Purchase of available-for-sale securities | |||||||||
1,193,632 | 1,171,603 | 589,520 | 195,427 | 162,001 | 274,368 | - | - | - | - |
Maturity and sale of available-for-sale securities | |||||||||
1,715,626 | 865,813 | 296,225 | 112,100 | 185,939 | 134,913 | - | - | - | - |
Purchase of marketable securities | |||||||||
- | - | - | - | - | - | - | 0 | - | 7 |
Sale of marketable securities | |||||||||
- | - | - | - | - | - | - | 0 | - | 0 |
Acquisition of Myonexus Therapeutics, Inc., net of cash acquired | |||||||||
172,556 | - | - | - | - | - | - | - | - | - |
Acquisition costs | |||||||||
- | - | - | - | - | - | - | 0 | - | 0 |
Net cash (used in) provided by investing activities | |||||||||
286,725 | -370,488 | -178,815 | -90,193 | 8,410 | -159,030 | -11,672 | -1,145 | -2,305 | -1,961 |
Cash flows from financing activities: | |||||||||
Proceeds from issuance of common stock to Roche | |||||||||
365,354 | 513,409 | 353,959 | 364,802 | 119,916 | 94,503 | - | - | - | - |
Proceeds from exercise of stock options and purchase of stock under the Employee Stock Purchase Program | |||||||||
36,601 | 50,222 | 15,224 | - | - | - | - | - | - | - |
Taxes paid related to net share settlement of equity awards | |||||||||
4,337 | - | - | - | - | - | - | - | - | - |
Proceeds from Term Loan | |||||||||
- | - | - | - | 20,000 | - | - | - | - | - |
Repayment of June 2015 and July 2017 Term Loan | |||||||||
- | 30,000 | 15,000 | 5,000 | - | - | - | - | - | - |
Proceeds from revolving line of credit | |||||||||
- | 235,872 | 39,708 | - | - | - | - | - | - | - |
Repayment of revolving line of credit | |||||||||
- | 235,954 | 39,645 | - | - | - | - | - | - | - |
Payment for debt extinguishment | |||||||||
- | 2,134 | - | - | - | - | - | - | - | - |
Repayment of mortgage loans and notes payable | |||||||||
- | 1,265 | 109 | 2,603 | 2,598 | 94 | 89 | - | - | - |
Purchase of capped call options | |||||||||
- | - | 50,901 | - | - | - | - | - | - | - |
Proceeds from convertible debt offering | |||||||||
- | - | 570,000 | - | - | - | - | - | - | - |
Debt issuance costs | |||||||||
689 | - | 15,154 | - | 399 | - | - | - | - | - |
Proceeds from exercise of stock options and purchase of stock under the Employee Stock Purchase Program | |||||||||
- | - | - | 20,930 | 10,889 | 9,746 | 145,986 | 178,681 | 32,380 | 2,561 |
Repayments of long-term debt | |||||||||
- | - | - | - | - | - | - | 85 | 81 | 77 |
Other financing activities, net | |||||||||
- | - | - | - | - | - | -226 | 0 | - | 0 |
Net cash provided by financing activities | |||||||||
642,554 | 530,150 | 888,082 | 378,129 | 147,808 | 104,155 | 145,671 | 178,596 | 32,299 | 2,484 |
Increase in cash, cash equivalents and restricted cash | |||||||||
472,816 | -228,998 | 477,271 | 42,116 | 6,753 | -183,414 | 69,304 | 147,757 | 6,315 | -14,686 |
Supplemental disclosure of cash flow information: | |||||||||
Cash paid during the period for interest | |||||||||
8,550 | 11,308 | 1,912 | 1,562 | 769 | 77 | 144 | 86 | 90 | 94 |
Cash paid during the period for income taxes | |||||||||
933 | 1,548 | 5,336 | - | - | - | - | - | - | - |
Supplemental schedule of non-cash investing activities and financing activities: | |||||||||
Purchase of restricted investment | |||||||||
- | 353 | - | - | 10,695 | - | 7,897 | - | - | - |
Maturity of restricted investment | |||||||||
- | - | 10,695 | - | - | 7,250 | - | - | - | - |
Shares withheld for tax included in accrued expenses | |||||||||
4,798 | - | - | - | - | - | - | - | - | - |
Accrued debt discount and issuance costs | |||||||||
5,000 | - | 625 | - | - | - | - | - | - | - |
Intangible assets included in accrued expenses | |||||||||
- | - | - | 1,163 | 335 | 270 | 195 | - | - | - |
Tenant improvement paid by Landlord | |||||||||
- | - | - | - | - | - | 6,214 | - | 0 | - |
Issuance of notes payable in relation to the purchase of certain real and personal property located in Andover, Massachusetts | |||||||||
- | - | - | - | - | 4,613 | - | - | - | - |
Accrued exit and legal fees for debts | |||||||||
- | - | - | 400 | 400 | - | - | - | - | - |
Intangible assets and property and equipment included in accrued expenses | |||||||||
1,181 | 5,421 | 2,525 | 1,186 | 318 | 277 | 3,964 | - | 0 | - |
Short-term securities-available-for-sale received in connection with the private offering | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Issuance of common stock in satisfaction of warrants | |||||||||
- | - | - | - | - | 11,785 | 78,214 | 32,191 | 643 | 0 |
Shares withheld for taxes | |||||||||
- | - | - | 2,168 | 182 | 34 | - | - | - | - |
Reclassification of long term investments to short term investments | |||||||||
- | 9,980 | - | - | - | - | - | - | - | - |
Issuance of common stock for building purchase | |||||||||
- | - | - | - | - | - | - | 0 | - | 0 |
Assumption of long-term debt for building purchase | |||||||||
- | - | - | - | - | - | - | 0 | - | 0 |
Issuance of common stock to acquire assets | |||||||||
- | - | - | - | - | - | - | 0 | - | 0 |
Assumption of liabilities to acquire assets | |||||||||
- | - | - | - | - | - | - | 0 | - | 0 |
December 2019 Term Loan [Member] | |||||||||
Proceeds from Term Loan | |||||||||
245,625 | - | - | - | - | - | - | - | - | - |
July 2017 Term Loan [Member] | |||||||||
Proceeds from Term Loan | |||||||||
- | - | 30,000 | - | - | - | - | - | - | - |